Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Front-line Therapy with Alemtuzumab (Campath®) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia

Protocol CLO222: A Phase II, Open-Label Study of Clofarabine in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia

Protocol AGLU01602: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha-Glucosidase (rhGAA) Treatment in Patients ≤ 6 Months Old with Infantile-Onset Pompe Disease (Glycogen Storage Disease Type II)

Protocol AGLU01702: An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha-Glucosidase (rhGAA) Treatment in Patients > 6 and ≤ 36 Months Old with Infantile-Onset Pompe Disease (Glycogen Storage Disease Type II)

Protocol AGLU02804: A Single Center, Open-Label, Bridging Study of the Safety, Pharmacokinetics and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) Treatment in Patients with Late-Onset Pompe Disease (Glycogen Storage Disease Type II)

Protocol RC 91-0110: An Evaluation of the Safety and Effectiveness of Recombinant, Human, Macrophage-Targeted β-Glucocerebrosidase.

Protocol ALID-006-01: A Multicenter, Multinational, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human Alpha-L-iduronidase in Patients with Mucopolysaccharidosis I.

Protocol ALID-003-99: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha-L-Iduronidase in Patients with Mucopolysaccharidosis I.

Protocol BIO7500-001: Enzyme Replacement Therapy in the Treatment of Mucopolysaccharidosis I.

Protocol RC 92-0501: An Extended Evaluation of the Safety and Effectiveness of Recombinant, Human-derived, Macrophage-Targeted β Glucocerebrosidase in Patients with Gaucher disease.

Protocol RC 92-0301: An Evaluation of Effectiveness of Different Dosing Schedules of Recombinant, Human, Macrophage-Targeted β-Glucocerebrosidase.

Protocol TSH92-0601: A Study of Safety and Effectiveness of Thyrogen.

Protocol TSH94-0301: Pharmacokinetic Assessment of Thyrogen® in Patients with Thyroid Cancer.

Protocol GTC-36-301: An Open Label, Cross-over Study of Renagel® and Calcium Acetate in Hemodialysis Patients.

Protocol GTC-10-201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of Renagel® in Lowering Serum Phosphorus in Hemodialysis Patients.

Protocol GTC-45-204: An Open Label, Dose Titration Study of Sevelamer Hydrochloride (Renagel®) in Chronic Renal Failure Patients Not Requiring Dialysis.

Protocol REN-002-01: Comparison of a Calcium-Free Phosphate Binder (Sevelamer) with a Calcium-Containing Phosphate Binder (Calcium Acetate) in the Treatment of Hyperphosphatemia in Children with Chronic Renal Failure

Protocol GTC-45-206: An Open Label, Dose Titration Study of Sevelamer Hydrochloride (Renagel®) in Pediatric Dialysis Patients.

Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel®) in Chronic Kidney Disease Patients.

Protocol GTC-68-209: A Randomized, Cross-Over Study to Compare Once a Day Sevelamer Dosing with Three Times per Day Sevelamer Dosing

Protocol REN-001-00: A Two-Year Follow-Up Study Comparing Sevelamer Hydrochloride (Renagel®) and Calcium-Based Binders in Hemodialysis Patients Treated According to Normal Clinical Practice.

Protocol No. GTC-36-302: An Open Label, Dose Titration Study of Renagel® in Hemodialysis Patients.

Protocol GTC-45-901: An Extended Use Study of Renagel® in Hemodialysis Patients.

Protocol GTC-02-101: A Randomized Double-Blind Placebo-Controlled Parallel-Design Evaluation of the Safety and Tolerance of Single and Multiple Oral Doses of 1, 2.5, and 5 Grams of Renagel® (Sevelamer Hydrochloride) in Normal Subjects

GTC-45-803: A Study to Determine the Effect of Sevelamer HCl (Renagel®) on Single Dose Metoprolol Tartrate (Lopressor®) Pharmacokinetics in Healthy Subjects.

GTC-45-804: A Study to Determine the Effect of Sevelamer (Renagel®) on Single Dose Enalapril Maleate (Innovace®) Pharmacokinetics in Healthy Subjects

Protocol GTC-10-801: Absorption of 14C-Renagel® (Sevelamer Hydrochloride) (500 µCi) in Healthy Young and Old Male and Female Volunteers

Protocol ICR013821: An Open Label Study to Assess the Potential Pharmacokinetic Interaction of Single Doses of Renagel® (Sevelamer Hydrochloride) with Warfarin in Healthy Volunteers

Protocol ICR013769: An Open Label Study to Assess the Potential Pharmacokinetic Interaction of Single Doses of Renagel® (Sevelamer Hydrochloride) with Digoxin in Healthy Volunteers

GTC-45-808: Effect of Phosphate Binders on Supplemental Iron Absorption in Healthy Subjects

Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH®) in Patients with B-Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy

Protocol GTC-49-301: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel®) and Calcium-Based Phosphate Binders in Hemodialysis Patients – Treat to Goal.

Protocol BCI-CH-125: Phase 2 Study of 1α-hydroxyvitamin D2 (1α-OH-D2) in the Treatment of Advanced Androgen Independent Prostate Cancer

Protocol GTC-10-202: An Open Label Dose Titration Study of Renagel® in Hemodialysis Patients.

GTC-45-807: Effect of Sevelamer Hydrochloride and Calcium Acetate on the Oral Bioavailability of Ciprofloxacin in Healthy Volunteers

THYR-007-00: Thyrogen® Compassionate Use Program Retrospective Data Collection and Analysis Protocol for Canada/United States of America.

Protocol THYR-008 -00: A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State.

TSH95-0101: A Study of the Safety and Efficacy of Thyrogen® (recombinant human TSH) in Detecting Well-Differentiated Thyroid Cancer by Radioiodine Whole Body Scanning and Thyroglobulin Testing.

Protocol BCI-CH-126: A Study of the Safety and Tolerance of Daily Oral Doxercalciferol Therapy for Secondary Hyperparathyroidism in End Stage Renal Disease Patients on Chronic Peritoneal Dialysis

Protocol BCI-CH-110: Effect of High Pulse Dose Oral 1α -Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

Protocol BCI-CH-112: Effect of Oral 1α -Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in Elderly Subjects with Secondary Hyperparathyroidism

Protocol BCI-CH-108-Memphis: A Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral 1α -Hydroxyvitamin D2 in Reducing Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

Protocol BCI-CH-108-LA: A Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral 1α -Hydroxyvitamin D2 in Reducing Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

SANG-93-3-K-THY-R: A Double-Blinded, Randomized, Multicenter Phase III Clinical Trial of Thymoglobulin® vs. Atgam® in the Treatment of Acute Graft Rejection Episodes Following Renal Transplantation in Adults

Protocol BCI-CH-102: Effect of Extended Oral Administration of 1α -Hydroxyvitamin D2 on Intestinal Calcium Absorption and Bone Mineral Density in Postmenopausal Osteoporotic Women

Protocol BCI-CH-120: A Multicenter, Open-label, Parallel Design, Comparative Study of the Efficacy and Safety of Intravenous 1α -Hydroxyvitamin D2 (Hectorol®) to Intravenous Calcitriol (Calcijex®) in Reducing Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

Protocol BCI-CH-144: A Phase 4, Single-center, Open-label, Randomized Study to Determine Clinically Appropriate Doses of Doxercalciferol Injection when Converting from Paricalcitol Injection for Secondary Hyperparathyroidism in ESRD Patients on Hemodialysis

Protocol BCI-CH-114-Memphis: A Multicenter, Open-label Study of the Efficacy and Safety of Intravenous 1α-Hydroxyvitamin D2 in Reducing Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

Protocol BCI-CH-119: Effect of Oral 1α-Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in Patients with Mild to Moderate Chronic Renal Failure

Protocol BCI-CH-114-LA: A Multicenter, Open-label Study of the Efficacy and Safety of Intravenous 1α-Hydroxyvitamin D2 in Reducing Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

ALID-014-02: A Phase II Open-Label Clinical Trial of Recombinant Human Alpha-l-iduronidase (Aldurazyme®) to Evaluate the Safety and Pharmacokinetics in Mucopolysaccharidosis I (MPS I) Patients Less Than 5 Years Old

Protocol GTC-36-203: A Randomized, Open Label, Dose Titration Study of Renagel® Phosphate Binder versus Renagel® Phosphate Binder with Calcium Carbonate in Hemodialysis Patients.

SANG-96-3-K-THY-I: A Randomized, Double-Blinded Comparison of Thymoglobulin® vs Atgam for Induction Immunosuppressive Therapy in Adult Renal Transplant Recipients

SMC-101-1002: A Prospective, Open Label, Multicenter, Phase IIB Clinical Trial of Thymoglobulin® as Induction Immunosuppression for the Prevention of Acute Rejection in Pediatric Renal Transplant Recipients

SMC-101-1007, SMC-101-1008, and SMC-101-1009: Peripheral Vein Administration of Thymoglobulin® for Induction Therapy in Adult Renal Allograft Recipients

RC96-1101: A Study of the Efficacy of Cerezyme® in Treating Skeletal Disease in Patients with Type 1 Gaucher Disease

Protocol CLO212. A Phase II, Open-Label Study of Clofarabine in Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Protocol BCI-CH-115: Effect of Oral 1α-Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in Patients with Mild to Moderate Chronic Renal Failure

Protocol BCI-CH-106: Effect of Oral 1α-Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in End Stage Renal Disease Patients on Hemodialysis

Protocol SMC-534-1003: Short Course Thymoglobulin® for Induction Immunosuppressive Therapy in Adult Renal Allograft Recipients

Protocol AGAL-019-01. A Cautious Graded Rechallenge With Intravenous r-hαGAL: A Multicenter, Open-Label Safety Study Of Fabry Patients Who Have Previously Tested Serum Immunoglobulin E Positive To r-hαGAL Or Who Had Positive Skin Tests To r-hαGAL

Protocol FB9702-01: Pharmacokinetic and Pharmacodynamic Evaluation of Recombinant Human α Galactosidase (r-hα GAL) Replacement in Patients with Fabry Disease: An Open-Label, Multi-Dose, Dose-Finding Study.

Protocol AGAL-022-02: A Phase 2, Randomized, Open Label, Dose-Ranging, Multiple Dose Study of Fabrazyme® In Patients with Fabry Disease and with Severe Renal Disease.

Protocol AGAL-006-99: An Open-Label Extension Study of the Safety and Efficacy of Recombinant Human α-Galactosidase A (r-hα GAL) Replacement Therapy in Patients with Fabry Disease who Participated in Protocol No. FB9702-01.

Protocol AGAL-1-002-98. A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study of the Safety And Efficacy of Recombinant Human α -Galactosidase (r-h α GAL) Replacement in Patients with Fabry Disease.